Biology-Guided Radiation Therapy for the Treatment of Patients With Bone Metastases
Part of paid clinical trials in Duarte, California.
- Sponsor
- City of Hope Medical Center
- Study ID
- NCT06549478
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Metastatic Malignant Neoplasm in the Bone
- Metastatic Malignant Solid Neoplasm
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Computed Tomography — PROCEDUREUndergo PET/CT
- Image Guided Radiation Therapy — RADIATIONUndergo BgRT
- Positron Emission Tomography — PROCEDUREUndergo PET/CT
- Questionnaire Administration — OTHERAncillary studies
Study Details
This clinical trial tests the safety and effectiveness of a single-dose treatment of biology-guided radiation therapy (BgRT) in treating patients with painful cancer that has spread from where it first started (primary site) to the bone (bone metastases). Bone metastases can result in significant pain and reduction in quality of life. Single fraction radiation therapy (SFRT) can produce equivalent pain relief compared to multi-fraction radiation therapy, but SFRT treatments generally lead to higher rates of retreatment. BgRT is a new and innovative form of radiation delivery that uses a signal generated by positron emission tomography to guide external beam radiation therapy. It is a technology breakthrough that uses live, continuously updated data throughout the entire treatment session to determine exactly where to deliver radiotherapy to biologically active tumors. Giving BgRT may be safe and effective in treating patients with painful bone metastases.
Key Dates
- First listed
- Aug 12, 2024
- Start date
- Jul 26, 2024
- Status verified
- Sep 2025
- Primary completion
- Jan 26, 2027
- Completion
- Jan 26, 2027
Study Design
- Enrollment
- 24 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment (BgRT)Patients undergo a single fraction of BgRT on day 0. Patients undergo PET/CT on study and optionally during follow up.
Primary Outcome Measure
Incidence of adverse events [ Time Frame: Up to 1 year follow-up ]
Central Contacts
- Yi-Jen Chen, MD626-218-4589
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| City of Hope Medical Center | Duarte | California | 91010 | Yi-Jen Chen (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Duarte, CA
Related Studies
- Collection and Storage of Tissue and Blood Samples From Patients With CancerRecruiting · National Cancer Institute LAO · Fort Smith, Arkansas
- Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple MyelomaRecruiting · University of Southern California · Duarte, California
- Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid TumorsPHASE1 · Recruiting · Anusha Kalbasi · Duarte, California
- PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric CancerPHASE1 · Recruiting · City of Hope Medical Center · Duarte, California